By leveraging the company’s innovative development platform, MapLight has already brought two novel therapeutics into the clinic, with more on the horizon. Focused on solutions that serve populations currently struggling with either no treatment options or limited options with significant safety liabilities, MapLight’s initial therapeutics are aimed at safely targeting key symptoms of Autism Spectrum Disorder, Dyskinesia in Parkinson’s Disease, and Schizophrenia.
Learn more about our ASD clinical study » 1 of 3 Learn more about our Schizophrenia studies » 2 of 3 Learn more about our Parkinson’s Disease studies » 3 of 3
MapLight's focus on indications with high unmet medical need
Autism Spectrum Disorder
Dyskinesia in Parkinson’s Disease